RT Journal Article
SR Electronic
T1 IgG serology in health care and administrative staff populations from 7 hospitals representative of different exposures to SARS-CoV-2 in Lombardy, Italy
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.24.20111245
DO 10.1101/2020.05.24.20111245
A1 Maria Teresa Sandri
A1 Elena Azzolini
A1 Valter Torri
A1 Sara Carloni
A1 Michele Tedeschi
A1 Massimo Castoldi
A1 Alberto Mantovani
A1 Maria Rescigno
YR 2020
UL http://medrxiv.org/content/early/2020/05/26/2020.05.24.20111245.abstract
AB Lombardy is one of the regions in Italy most affected by COVID-19. We assessed the diffusion of the virus via testing plasma anti-SARS-CoV-2 IgG antibodies in 3985 employees of 7 different hospitals, located across the Lombardy region in areas with different exposure to the epidemic. Subjects filled an anamnestic questionnaire to self-report on COVID-19 symptoms, co-morbidities, smoking, regular or smart-working, and the exposure to COVID-19-infected individuals. We show that the number of individuals exposed to the virus depended on the geographical area where the hospital was located and ranged between 3 to 43% which correlated with the incidence of COVID-19 in Lombardy. There was a higher prevalence of females than males positive for IgG, however the level of antibodies was similar, suggesting a comparable magnitude of the response. We observed 10% of IgG positive asymptomatic individuals and another 20% with one or two symptoms. 81% of individuals presenting both anosmia/ageusia and fever resulted SARS-CoV-2 infected. IgG positivity correlated with family contacts.In conclusion, the frequency of IgG positivity and SARS-CoV-2 infection is dependent on the geographical exposure to the virus and to extra-hospital exposure.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04387929Funding StatementThe study was funded by the Italian Ministry of Health (Ricerca Corrente)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Istituto clinico Humanitas and Humanitas Gavazzeni Ethical committees approved the protocol.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available upon request